Table 6. Treatment strategies for newly-diagnosed Burkitt lymphoma.

Stratification	Category I recommendations	Category II recommendations
CODOX-M-R, cyclophosphamide, vincristine, doxorubicin, methotrexate and rituximab; CODOX-M/IVAC-R, cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, cytarabine and rituximab; R-hyper-CVAD/MA, rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab.
Low risk (normal LDH; stage I with complete resection of abdomen lesion, or single lesion outside abdomen <10 cm)	CODOX-M-RHyper CVAD/MA-R (Level 2A evidence)	DA-EPOCH-R (Level 2A evidence)
High risk (stage I with bulky abdomen lesion, or single lesion outside abdomen >10 cm, or stage II−IV)	CODOX-M/IVAC-R Hyper CVAD/MA-R (Level 2A evidence)	DA-EPOCH-R (Level 2A evidence)